



3745 #4

Patent Application
Attorney Docket No. PC9978A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 18th day of June, 2001.

By _____

(Signature of person mailing)
ROY F. WALDRON

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: F. ITO et al.

APPLICATION SERIAL NO.: 09/753,954 : Examiner: Not Assigned

FILING DATE: January 3, 2001 : Group Art Unit: 3745

TITLE: BENZIMIDAZOLE COMPOUNDS AS :
ORL1-RECEPTOR AGONISTS

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL LETTER

Applicants submit herewith an Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97(b) and 1.98 with accompanying Form PTO-A820 (2x). This Statement is being filed later than three months of the filing date of the above-captioned application, but before the mailing date of a first Office Action on the merits.

Accordingly, there is no fee required for the filing of this Statement. Nonetheless, the Commissioner is hereby authorized to charge any other additional fees which may be required under 37 C.F.R. §§ 1.16 and 1.17, or to credit any overpayment, to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Respectfully submitted,

Roy F. Waldron
Attorney for Applicant(s)
Reg. No. 42,208

Date: 6/15/2001
Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-5086

RECEIVED
JUN 22 2001
TC 3700 MAIL ROOM



Patent Application
Attorney Docket No. PC9978A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 15th day of June, 2001.

By _____

(Signature of person mailing)
ROY F. WALDRON

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: F. ITO et al. :

APPLICATION SERIAL NO.: 09/753,954 : Examiner: Not Assigned

FILING DATE: January 3, 2001 : Group Art Unit: 3745

TITLE: BENZIMIDAZOLE COMPOUNDS AS :
ORL1-RECEPTOR AGONISTS :
:

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

RECEIVED
JUN 22 2001
TC 3700 MAIL ROOM

Applicant herewith makes available to the U.S. Patent and Trademark Office this Information Disclosure Statement pursuant to 37 C.F.R. § 1.98 and a Form PTO-FB-A820 (2x). This Information Disclosure Statement contains a listing of references, copies of which are enclosed herewith. A copy of the European Search Report for counterpart European application 00311316.4 is also enclosed herewith. This Statement is being made prior to the mailing of an Office Action on the merits.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accordance with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with Applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Patent Application
Attorney Docket No. PC9978A

The references listed on the PTO-FB-A820 are as follows:

U.S. Patents

US 3,318,900, issued May 9, 1967
US 3,963,727, issued June 15, 1976

Foreign Patent Documents

WO 00/08013, published February 17, 2000
WO 98/54168, published December 3, 1998
EP 0 990653, published April 5, 2000
WO 97/40035, published October 30, 1997

Other Documents

Patent Abstract of Japan, Vol. 013, No. 249 (C-605), (9 June 1989)
(JP 01 056617 A, 3 March 1989)

Patent Abstract of Japan, Vol. 1999, No. 03, (31 March 1999)
(JP 10 330377 A, 15 December 1998)

A favorable response is earnestly solicited.

Respectfully submitted,

Date: 6/15/2001



Roy F. Waldron
Attorney for Applicant(s)
Reg. No. 42,208

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-5086